▶ MAZDUTIDE · SUBTOPIC · SAFETY PROFILE
MAZDUTIDE Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of MAZDUTIDE.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of MAZDUTIDE. Severity, frequency, and attribution depend on the source publication.
- GI: nausea, vomiting, diarrhea
- Injection-site reactions
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for MAZDUTIDE.
- Class effect · sulfonylureas/insulin
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for MAZDUTIDE in the published record:
- History of MTC or MEN2
FDA REGULATORY STATUS
Investigational outside China. Not FDA-approved.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List.
OTHER JURISDICTIONS
China · China NMPA NDA submitted for obesity 2024; review ongoing.
SAFETY Q+A FROM LITERATURE
▶ Is mazdutide approved?
China NMPA review ongoing for obesity (as of 2026-05). Not FDA-approved.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Zhao H, et al.. Mazdutide IBI362 in obese Chinese adults: dose-finding phase 2. JAMA Netw Open 2024. link
- Innovent Biologics / Eli Lilly. A phase 3 study of mazdutide in Chinese participants with overweight or obesity (GLORY-1). ClinicalTrials.gov · Phase 3 2024. NCT05216575. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19